Rosuvastatin + Atorvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronary Atherosclerosis
Conditions
Coronary Atherosclerosis
Trial Timeline
Jan 1, 2008 → Jun 1, 2011
NCT ID
NCT00620542About Rosuvastatin + Atorvastatin
Rosuvastatin + Atorvastatin is a phase 3 stage product being developed by AstraZeneca for Coronary Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00620542. Target conditions include Coronary Atherosclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00683618 | Phase 3 | Completed |
| NCT00620542 | Phase 3 | Completed |
| NCT00427960 | Approved | Terminated |
| NCT00395486 | Approved | Completed |
| NCT00296400 | Phase 2 | Completed |
| NCT00296387 | Phase 3 | Completed |
| NCT00329173 | Phase 3 | Completed |
| NCT00239330 | Phase 3 | Completed |
| NCT00653965 | Phase 3 | Completed |
| NCT00653588 | Phase 3 | Completed |
| NCT00654225 | Phase 3 | Completed |
| NCT00654485 | Phase 3 | Completed |
| NCT00653744 | Phase 3 | Completed |
Competing Products
20 competing products in Coronary Atherosclerosis